Answers are grounded in this paper and cite their sources.
Nivolumab v kombinaci s nĂzkou dĂĄvkou ipilimumabu pĹinesly robustnĂ a dlouhodobĂ˝ klinickĂ˝ pĹĂnos se zvlĂĄdnutelnĂ˝m bezpeÄnostnĂm profilem u dĹĂve lĂŠÄenĂ˝ch pacientĹŻ s metastatickĂ˝m kolorektĂĄlnĂm karcinomem (mCRC) s vysokou mikrosatelitovou nestabilitou/defektem mismatch repair proteinĹŻ (MSI-H/dMMR) pĹi mediĂĄnu sledovĂĄnĂ 13,4 a 25,4 mÄsĂcĹŻ v multikohortovĂŠ studii fĂĄze 2 CheckMate 142. Na ASCO 2022 byla prezentovĂĄna data ĂşÄinnosti a bezpeÄnosti 5letĂŠho sledovĂĄnĂ. ĂÄinek lĂŠÄby potvrzujĂ i zkuĹĄenosti v klinickĂŠ praxi a konkrĂŠtnĂ pĹĂpad pacienta.
No takes yet. Share an insight, caveat, or question.
Beatric Bencsiková (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: